47.83
-0.33 (-0.69%)
| Penutupan Terdahulu | 48.16 |
| Buka | 47.85 |
| Jumlah Dagangan | 347,043 |
| Purata Dagangan (3B) | 780,450 |
| Modal Pasaran | 1,228,861,184 |
| Harga / Buku (P/B) | 4.76 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| EPS Cair (TTM) | -3.23 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.07% |
| Nisbah Semasa (MRQ) | 33.87 |
| Aliran Tunai Operasi (OCF TTM) | -84.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -53.00 M |
| Pulangan Atas Aset (ROA TTM) | -19.03% |
| Pulangan Atas Ekuiti (ROE TTM) | -26.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Tourmaline Bio, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Nilai 35% | 0.0 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | 0.0 |
| Masa 35% | -2.0 |
| AI Technical info | NA |
| Osilator Teknikal info | 0.0 |
| Purata Bergerak Teknikal info | -5.0 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -22.5% |
| Persetujuan Tonggak | ×1.00 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | -1.7 |
| Skor Akhir | -0.85 |
|
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 21.93% |
| % Dimiliki oleh Institusi | 90.21% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |